NEW YORK (GenomeWeb) – NanoString Technologies said today that it has made an agreement to sell 3 million shares of its common stock at $16.75 per share with RW Baird as the sole underwriter in a public offering pursuant to NanoString's existing shelf registration statement filed in 2014.

The firm has also granted Baird a 30-day option to purchase up to an additional 450,000 shares of common stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.